, Volume 15, Issue 4, pp 1256-1257
Date: 01 Feb 2008

Nodal Micrometastases Status—Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

To the Editor

Should nodal micrometastatic status be considered for decision-making chemotherapy in node-negative breast cancer? A recent report by Chen et al. in the Journal1 highlights this controversial issue. Micrometastases in lymph nodes is a hot topic in surgical and medical oncology not only for breast cancer but also for many other solid tumors including melanoma, gastric, and other cancers.24 Available data in sentinel node biopsy and routine lymphadenectomy provide conflicting results for the impact of micrometastatic disease on survival.

Based on an analysis of the Surveillance, Epidemiology, and End Results (SEER) database for 209,720 breast cancer patients treated in the USA between 1992 and 2003, Chen and colleagues address clinically key questions1 not only in a univariate but also in a multivariate analysis. N1 micrometastatic disease (N1mi) was a significant prognostic indicator. The authors suggest the need for prospective studies considering N1mi as a stratification